InsiderTrades

Form 4 for AARD Aardvark Therapeutics, Inc.

Accepted 2025-02-19 00:00:00 ET · period of report 2025-02-14 · accession 0000950170-25-023253 · SEC index · Original document

Summary rows

Aggregated the way they appear in lists: one row per insider, transaction code and security table.

X Filed Traded Ticker Insider Title Type Price Qty Owned ΔOwn Value
D 2025-02-19 2025-02-14 AARD Lee Tien-Li CEO, Dir, 10% P - Purchase $16.00 +16.5K 1.50M +1% +$264.7K
D 2025-02-19 2025-02-14 AARD Lee Tien-Li CEO, Dir, 10% C - Cnv Deriv — +41.3K 1.48M +3% —
D 2025-02-19 2025-02-14 AARD Lee Tien-Li CEO, Dir, 10% C - Cnv Deriv $0.00 -350.0K 0 -100% $0

Purchase Sale Sale after option exercise All abbreviations

Every reported transaction

#TableSecurityDateCodeA/DSharesPriceOwned afterOwnExercise / expiryUnderlyingFootnotes
1 Common Common Stock 2025-02-14 P A 16,542 $16.00 1,496,175 D — —
2 Common Common Stock 2025-02-14 C A 41,303 — 1,479,633 D — — (F1) The Series A Convertible Preferred Stock of Aardvark Therapeutics, Inc. (the "Issuer") automatically converted on an 8.474-for-1 basis into shares of the Issuer's common stock ("Common Stock") immediately prior to the closing of the Issuer's initial public offering of its Common Stock. The Series A Convertible Preferred Stock had no expiration date.
3 Derivative Series A Convertible Preferred Stock 2025-02-14 C D 350,002 $0.00 0 D — · — to — 41,303 Common Stock (F1) The Series A Convertible Preferred Stock of Aardvark Therapeutics, Inc. (the "Issuer") automatically converted on an 8.474-for-1 basis into shares of the Issuer's common stock ("Common Stock") immediately prior to the closing of the Issuer's initial public offering of its Common Stock. The Series A Convertible Preferred Stock had no expiration date.